Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
about
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysisProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureThe questionable use of unequal allocation in confirmatory trialsLevomilnacipran for the treatment of major depressive disorder: a reviewA pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertralineLithium monotherapy increases ACTH and cortisol response in the DEX/CRH test in unipolar depressed subjects. A study with 30 treatment-naive patientsAccounting for Behavior in Treatment Effects: New Applications for Blind TrialsMajor Depression Detection from EEG Signals Using Kernel Eigen-Filter-Bank Common Spatial PatternsFluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Experimental medication treatment approaches for depression.Certainty of genuine treatment increases drug responses among intellectually disabled patients.A randomised cross-over study assessing the "blue pyjama syndrome" in major depressive episode.Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.Current nosology of treatment resistant depression: a controversy resistant to revisionAntidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies.[Placebo response: in studies on pain and under other clinical conditions].Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression.Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebosMagnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews.The role of patient expectancy in placebo and nocebo effects in antidepressant trialsRole of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.Lurasidone: a new drug in development for schizophrenia.SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trialThe effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs.Should we treat depression with drugs or psychological interventions? A reply to Ioannidis.How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.Placebo eff ects in psychiatry: mediators and moderators.Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.A new paradigm for the prediction of antidepressant treatment responseAge and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicineEfficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trialsTherapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels?Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials.Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos.Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials.How Health Professionals Conceptualize and Represent Placebo Treatment in Clinical Trials and How Their Patients Understand It: Impact on Validity of Informed ConsentDoes psychomotor retardation define a clinically relevant phenotype of unipolar depression?Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy.
P2860
Q26779632-9E27513F-1804-42A4-9E3D-1D419CFAFB4FQ26796436-096B13FC-742F-4D41-8877-D3B72F77A768Q27693918-F9809DB6-30A8-44C6-981E-3AF96DF4FB00Q28083216-82CD1100-D5FD-4933-92CD-1115AEA959AFQ28286878-B0392D33-9A50-48EC-9B3D-DD9C0DBCC233Q28478124-BCE5C2ED-498E-4FD7-9F56-3575FE385724Q28548112-26C4CC4C-2CF0-4D55-85C9-EF8F77FE951CQ33459391-3274A18D-9ABB-40B1-9230-C2026B805D6EQ33488312-E38A34C8-00E5-46F7-87C2-8528401D7D78Q33635577-CAEC5DC2-8AAB-4EAB-B533-E3B1188CED56Q33726997-EC0032B3-1C13-47B2-A365-74479236E907Q33752833-C22813E4-4928-4F60-B3DB-3E01C93F808EQ33887831-E48C9845-996F-4630-821B-D7F0AB14B439Q33920910-AF383FC2-6A19-4050-86F4-F53A013EDC25Q33936735-823CFFD5-5398-4478-B3BD-6BAA686CD6CEQ33938286-0FD34AD4-F074-4C67-A37A-434A77DB7B15Q34229109-0AC715B8-D00F-4F57-A3F0-CB4ABC1A9483Q34322113-7A86F626-7CBF-4BE9-989F-B57D07C25FDCQ34326396-77DC72D9-9D0D-400A-8B42-70D1C9E18045Q34396650-88E1716D-36DA-47D7-A4C5-E3CC836B06D2Q34458264-F6EB16E9-BA7A-4005-9D93-AC64ADB5EA0BQ34589878-B9D583CD-62AC-4A61-BBD1-BBA714ABCA78Q34634132-0436C3E1-2DEF-4690-BDC2-A6B4D97DCB11Q35005165-D44C2FBC-1566-4561-917E-36F9AD9A371AQ35036979-97576697-4A43-47D9-8BB7-3B8D6E87DCFAQ35059000-6D4F11AA-487D-4307-8476-26FB421B181CQ35069464-309E2D9D-DEC1-4C5B-B76E-26A5B7E87E85Q35174992-3AE14CA2-B255-4A39-A68C-F393BD78B405Q35207492-224CEB80-F7C3-4ACE-B5F9-F59F90387FCFQ35237042-90325DAE-100D-4ABE-9DFA-B70070306FD8Q35237120-D6999BC4-6476-4AE8-A997-3AD15E168A96Q35513153-AED7ABA2-BE64-416A-A101-0535E77172D6Q35544278-CA5D39B6-E554-4FA1-8175-7FFE5E56F901Q35562674-9CF225B7-B75C-46F2-8B6B-92FE77224695Q35694450-DC3ED63E-5ACA-4CCB-BB85-352B89C91522Q35784840-CD13C7D2-FFB3-4D31-BC34-07A8C103B424Q35833315-92CA2BB7-F4C4-488E-B625-6A22024DCCF1Q36022279-62F836EF-E0DB-4E0A-90A6-A7BBA54E9CE4Q36070285-74CE12B6-433E-4CB7-9CB0-ABD18A06808BQ36144704-7F054FE5-843A-4599-8D5F-4F144E9DA15B
P2860
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Does the probability of receiv ...... omized clinical trials in MDD.
@en
Does the probability of receiv ...... omized clinical trials in MDD.
@nl
type
label
Does the probability of receiv ...... omized clinical trials in MDD.
@en
Does the probability of receiv ...... omized clinical trials in MDD.
@nl
prefLabel
Does the probability of receiv ...... omized clinical trials in MDD.
@en
Does the probability of receiv ...... omized clinical trials in MDD.
@nl
P31
P1476
Does the probability of receiv ...... omized clinical trials in MDD.
@en
P2093
George I Papakostas
Maurizio Fava
P356
10.1016/J.EURONEURO.2008.08.009
P407
P577
2008-09-26T00:00:00Z